Developing Botswana Laboratory Capacity in HIV Genomics and HIV Cure
Project Number5G11TW012503-03
Contact PI/Project LeaderGASEITSIWE, SIMANI
Awardee OrganizationBOTSWANA-HARVARD AIDS INSTITUTE
Description
Abstract Text
Project Summary
Botswana has been one of the countries most affected by HIV-1 and has always been in the top 3
countries by HIV-1 prevalence for the past 20 years. The country has responded gallantly by providing free
antiretroviral therapy (ART) to persons living with HIV-1 (PLWH) in 2002 and an aggressive combination of
prevention strategies. This has resulted in reduced HIV-1 incidence and associated mortality and the country
was the third globally to reach the UNAIDS 95-95-95 targets of HIV-1 diagnosis, treatment, and viral
suppression. Since its inception in 1996, the Botswana Harvard AIDS Institute Partnership (BHP) has
conducted investigator-initiated clinical trials, observational and epidemiologic studies, laboratory-based
studies, and implementation science research. BHP laboratory also carries out molecular virology research
on HIV and this research has been instrumental in molecular characterizing HIV-1 subtype C, which
predominates in Botswana and Southern Africa. We draw upon the depth and breadth of the experience
gained over more than 2 decades of investigator-initiated research, training, and capacity building to increase
access to HIV-1 genomics training. Since 2017, we have invested in implementing pathogen agnostic next-
generation sequencing which was critical in the first sequencing of the SARS-CoV-2 Omicron variant of
concern in Botswana. Working with our collaborators we have also established cohorts of very early treated
infants and adolescents for understanding HIV-1 reservoirs.
We, therefore, aim through this application to strengthen BHP in HIV-1 genomics and molecular virology
capacity in Botswana and increase access to pathogen genomics in the sub-Saharan Africa region as a
center of excellence. The capacity developed here will be crosscutting for virologic studies and will thus be
instrumental in BHP lab’s continued diversification into research on other emerging pathogens of global public
health interest. To achieve this, we aim to 1) develop and advance BHP as an HIV-1 genomics regional
center of excellence. We will leverage the expertise in pathogen genomics developed over the past 20 years
to facilitate capacity building by hosting courses in HIV-1 sequencing, bioinformatic analysis, and sequence
data interpretation. Building on our collaboration with the University of Botswana, Harvard T.H. Chan School
of Public Health (HSPH), and the Ragon Institute of MGH, MIT & Harvard, we will target students and faculty
from local and regional Institutions for the training. We will facilitate the development of HIV genomics, make
them accessible to local universities and other countries in the region, and 2) To establish HIV-1 Reservoir
assays in support of the ongoing and planned HIV-1 cure studies at BHP. We plan to set up assays for the
assessment of HIV-1 reservoirs in PLWH in Botswana. Laboratory scientists will be trained on a number of
these assays at the collaborator’s laboratory in Boston (Ragon Institute of MGH, MIT & Harvard). We will
also train and establish capacity for the bioinformatic analysis for HIV-1 reservoir characterization.
1
Public Health Relevance Statement
Narrative
The project aims to develop specialized HIV-1 genomics laboratory training modules at BHP to build capacity
for laboratory professionals and university students on HIV-1 genomics, and HIV-1 cure-related research in
Botswana and the region. The proposed project will increase the human capacity for conducting advanced
HIV-1 genomics research and establishing local capacity for HIV-1 Reservoirs studies to contribute toward
HIV cure-related research in southern Africa. Successful implementation of this project will also result in the
establishment of a core facility and center of excellence for pathogen genomics, and support future NIH-
funded HIV-1 cure projects.
1
NIH Spending Category
No NIH Spending Category available.
Project Terms
Acquired Immunodeficiency SyndromeAdolescentAffectAfrica South of the SaharaAfricanAnti-Retroviral AgentsAreaBioinformaticsBiological AssayBostonBotswanaCertificationClinicalClinical ResearchClinical TrialsCollaborationsCore FacilityCountryDNADataData AnalysesDevelopmentDiagnosisDrug resistanceEducational workshopEvolutionFacultyFlow CytometryFundingFutureGenerationsGenomic SegmentGenomicsGenotypeGrantHIVHIV-1HIV-1 vaccineHealth PersonnelHumanIncidenceInfantInstitutionInvestigator-Initiated ResearchInvestmentsKnowledgeLaboratoriesLaboratory ScientistsMolecularMolecular VirologyMother-to-child HIV transmissionObservational StudyOutputPatientsPersonsPharmaceutical PreparationsPrevalencePrevention strategyPublic HealthPublic Health SchoolsResearchResearch PersonnelRestSARS-CoV-2 B.1.1.529ScientistSouthern AfricaStudentsTrainingTraining ActivityUnited States National Institutes of HealthUniversitiesVaccine DesignViralWorkWorld Health Organizationantiretroviral therapycohortcommunity advisory boardemerging pathogenepidemiology studyexperiencegraduate studentimplementation scienceimprovedinterestlaboratory experiencemembermortalitynext generation sequencingpathogenpathogen genomicspressureprofessional studentsprogramsresistance mutationskillssuccesstreatment programuniversity studentvariants of concernvirtual
John E. Fogarty International Center for Advanced Study in the Health Sciences
CFDA Code
989
DUNS Number
538435473
UEI
SJ9HKUMEGZ48
Project Start Date
15-May-2023
Project End Date
28-February-2026
Budget Start Date
01-March-2025
Budget End Date
28-February-2026
Project Funding Information for 2025
Total Funding
$99,403
Direct Costs
$92,040
Indirect Costs
$7,363
Year
Funding IC
FY Total Cost by IC
2025
John E. Fogarty International Center for Advanced Study in the Health Sciences
$99,403
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5G11TW012503-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5G11TW012503-03
Patents
No Patents information available for 5G11TW012503-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5G11TW012503-03
Clinical Studies
No Clinical Studies information available for 5G11TW012503-03
News and More
Related News Releases
No news release information available for 5G11TW012503-03
History
No Historical information available for 5G11TW012503-03
Similar Projects
No Similar Projects information available for 5G11TW012503-03